image
Healthcare - Medical - Devices - NASDAQ - US
$ 5.24
1.35 %
$ 2.65 M
Market Cap
0.22
P/E
1. INTRINSIC VALUE

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus.[ Read More ]

The intrinsic value of one RSLS stock under the base case scenario is HIDDEN Compared to the current market price of 5.24 USD, ReShape Lifesciences Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart RSLS

image
FINANCIALS
8.68 M REVENUE
-22.79%
-14.6 M OPERATING INCOME
45.94%
-11.4 M NET INCOME
75.36%
-17 M OPERATING CASH FLOW
22.56%
-10 K INVESTING CASH FLOW
89.13%
17.6 M FINANCING CASH FLOW
461.47%
2.29 M REVENUE
16.64%
-1.76 M OPERATING INCOME
14.26%
-1.58 M NET INCOME
0.88%
-311 K OPERATING CASH FLOW
77.08%
0 INVESTING CASH FLOW
0.00%
0 FINANCING CASH FLOW
0.00%
Balance Sheet Decomposition ReShape Lifesciences Inc.
image
Current Assets 10.3 M
Cash & Short-Term Investments 4.46 M
Receivables 1.66 M
Other Current Assets 4.18 M
Non-Current Assets 367 K
Long-Term Investments 0
PP&E 310 K
Other Non-Current Assets 57 K
Current Liabilities 3.78 M
Accounts Payable 1.69 M
Short-Term Debt 222 K
Other Current Liabilities 1.87 M
Non-Current Liabilities 223 K
Long-Term Debt 151 K
Other Non-Current Liabilities 72 K
EFFICIENCY
Earnings Waterfall ReShape Lifesciences Inc.
image
Revenue 8.68 M
Cost Of Revenue 3.13 M
Gross Profit 5.55 M
Operating Expenses 20.2 M
Operating Income -14.6 M
Other Expenses -3.25 M
Net Income -11.4 M
RATIOS
63.93% GROSS MARGIN
63.93%
-168.69% OPERATING MARGIN
-168.69%
-131.22% NET MARGIN
-131.22%
-170.90% ROE
-170.90%
-106.79% ROA
-106.79%
-217.10% ROIC
-217.10%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis ReShape Lifesciences Inc.
image
Net Income -11.4 M
Depreciation & Amortization 154 K
Capital Expenditures -43 K
Stock-Based Compensation 766 K
Change in Working Capital -4.13 M
Others -2.72 M
Free Cash Flow -17 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets ReShape Lifesciences Inc.
image
RSLS has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership ReShape Lifesciences Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
12 USD 1
6-9 MONTHS
7.31 USD 1
9-12 MONTHS
19.5 USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
11 months ago
Nov 30, 2023
Sell 8.97 USD
STANKOVICH THOMAS
Chief Financial Officer
- 39
0.23 USD
10 months ago
Dec 31, 2023
Sell 10.5 USD
STANKOVICH THOMAS
Chief Financial Officer
- 42
0.25 USD
8 months ago
Feb 29, 2024
Sell 7.31 USD
STANKOVICH THOMAS
Chief Financial Officer
- 43
0.17 USD
5 months ago
May 31, 2024
Sell 12 USD
STANKOVICH THOMAS
Chief Financial Officer
- 48
0.25 USD
1 year ago
Aug 04, 2023
Sell 154 USD
STANKOVICH THOMAS
Chief Financial Officer
- 108
1.43 USD
1 year ago
Aug 24, 2023
Sell 55.4 USD
STANKOVICH THOMAS
Chief Financial Officer
- 39
1.42 USD
1 year ago
Sep 01, 2023
Sell 105 USD
STANKOVICH THOMAS
Chief Financial Officer
- 118
0.89 USD
1 year ago
Oct 11, 2023
Sell 36.3 USD
STANKOVICH THOMAS
Chief Financial Officer
- 39
0.93 USD
1 year ago
Oct 25, 2023
Sell 35.4 USD
STANKOVICH THOMAS
Chief Financial Officer
- 131
0.27 USD
1 year ago
Jul 06, 2023
Sell 156 USD
STANKOVICH THOMAS
Chief Financial Officer
- 106
1.47 USD
1 year ago
Jun 30, 2023
Bought 26.9 K USD
STANKOVICH THOMAS
Chief Financial Officer
+ 17702
1.52 USD
1 year ago
Mar 31, 2023
Sell 283 USD
STANKOVICH THOMAS
Chief Financial Officer
- 109
2.6 USD
1 year ago
Apr 30, 2023
Sell 227 USD
STANKOVICH THOMAS
Chief Financial Officer
- 96
2.36 USD
1 year ago
May 31, 2023
Sell 236 USD
STANKOVICH THOMAS
Chief Financial Officer
- 98
2.41 USD
1 year ago
Jan 24, 2023
Sell 360 USD
STANKOVICH THOMAS
Chief Financial Officer
- 48
7.49 USD
1 year ago
Jan 24, 2023
Sell 824 USD
STANKOVICH THOMAS
Chief Financial Officer
- 110
7.4906 USD
1 year ago
Feb 02, 2023
Sell 2.09 K USD
STANKOVICH THOMAS
Chief Financial Officer
- 157
13.29 USD
1 year ago
Feb 28, 2023
Sell 438 USD
STANKOVICH THOMAS
Chief Financial Officer
- 103
4.25 USD
1 year ago
Nov 28, 2022
Sell 61.8 K USD
STANKOVICH THOMAS
Chief Financial Officer
- 364756
0.1695 USD
1 year ago
Dec 01, 2022
Sell 778 USD
STANKOVICH THOMAS
Chief Financial Officer
- 5144
0.1513 USD
1 year ago
Dec 01, 2022
Sell 334 USD
STANKOVICH THOMAS
Chief Financial Officer
- 2213
0.1509 USD
2 years ago
Nov 04, 2022
Sell 1.6 K USD
STANKOVICH THOMAS
Chief Financial Officer
- 5883
0.2725 USD
2 years ago
Nov 04, 2022
Sell 684 USD
STANKOVICH THOMAS
Chief Financial Officer
- 2510
0.2724 USD
2 years ago
Oct 04, 2022
Sell 1.63 K USD
STANKOVICH THOMAS
CFO
- 5809
0.2807 USD
2 years ago
Oct 04, 2022
Sell 699 USD
STANKOVICH THOMAS
CFO
- 2484
0.2812 USD
2 years ago
Sep 06, 2022
Sell 1.88 K USD
STANKOVICH THOMAS
Chief Financial Officer
- 4828
0.39 USD
2 years ago
Aug 05, 2022
Sell 2.22 K USD
STANKOVICH THOMAS
Chief Financial Officer
- 4728
0.47 USD
2 years ago
Aug 05, 2022
Sell 5.49 K USD
Bandy Barton P.
President and CEO
- 11674
0.47 USD
2 years ago
Jul 01, 2022
Sell 2.55 K USD
STANKOVICH THOMAS
Chief Financial Officer
- 4630
0.55 USD
2 years ago
Jul 01, 2022
Sell 6.29 K USD
Bandy Barton P.
President and CEO
- 11442
0.55 USD
2 years ago
Jun 01, 2022
Sell 2.59 K USD
Bandy Barton P.
President and CEO
- 2699
0.96 USD
2 years ago
Jun 01, 2022
Sell 4.3 K USD
STANKOVICH THOMAS
Chief Financial Officer
- 4478
0.96 USD
2 years ago
May 31, 2022
Bought 1.17 K USD
STANKOVICH THOMAS
Chief Financial Officer
+ 1228
0.95 USD
2 years ago
May 31, 2022
Bought 6.15 K USD
STANKOVICH THOMAS
Chief Financial Officer
+ 6539
0.94 USD
2 years ago
May 31, 2022
Bought 55.8 USD
STANKOVICH THOMAS
Chief Financial Officer
+ 60
0.93 USD
2 years ago
May 31, 2022
Bought 7.36 K USD
STANKOVICH THOMAS
Chief Financial Officer
+ 7995
0.92 USD
2 years ago
May 31, 2022
Bought 900 USD
STANKOVICH THOMAS
Chief Financial Officer
+ 1000
0.9 USD
2 years ago
May 31, 2022
Bought 178 USD
STANKOVICH THOMAS
Chief Financial Officer
+ 200
0.89 USD
2 years ago
May 31, 2022
Bought 2.55 K USD
STANKOVICH THOMAS
Chief Financial Officer
+ 2900
0.88 USD
2 years ago
May 31, 2022
Bought 67.9 USD
STANKOVICH THOMAS
Chief Financial Officer
+ 78
0.87 USD
2 years ago
May 05, 2022
Sell 8.79 K USD
Bandy Barton P.
President and CEO
- 11417
0.77 USD
2 years ago
May 05, 2022
Sell 3.49 K USD
STANKOVICH THOMAS
Chief Financial Officer
- 4529
0.77 USD
2 years ago
Apr 01, 2022
Sell 5.69 K USD
STANKOVICH THOMAS
Chief Financial Officer
- 5038
1.13 USD
2 years ago
Apr 01, 2022
Sell 12.5 K USD
Bandy Barton P.
President and CEO
- 11063
1.13 USD
2 years ago
Feb 28, 2022
Sell 3.88 K USD
STANKOVICH THOMAS
CFO
- 3658
1.06 USD
2 years ago
Feb 28, 2022
Sell 6.93 K USD
Bandy Barton P.
President and CEO
- 6538
1.06 USD
2 years ago
Jan 31, 2022
Sell 10.2 K USD
Bandy Barton P.
President and CEO
- 8324
1.22 USD
2 years ago
Jan 31, 2022
Sell 4.49 K USD
STANKOVICH THOMAS
Chief Financial Officer
- 3684
1.22 USD
2 years ago
Jan 04, 2022
Sell 12.8 K USD
Bandy Barton P.
President and CEO
- 7150
1.79 USD
2 years ago
Jan 04, 2022
Sell 5.64 K USD
STANKOVICH THOMAS
Chief Financial Officer
- 3171
1.78 USD
2 years ago
Dec 02, 2021
Sell 24.6 K USD
Bandy Barton P.
President and CEO
- 13427
1.83 USD
2 years ago
Dec 02, 2021
Sell 7.86 K USD
STANKOVICH THOMAS
Chief Financial Officer
- 4304
1.827 USD
3 years ago
Nov 18, 2021
Bought 40.4 K USD
STANKOVICH THOMAS
Chief Financial Officer
+ 20000
2.02 USD
3 years ago
Nov 02, 2021
Sell 36.3 K USD
Bandy Barton P.
President and CEO
- 13505
2.69 USD
3 years ago
Nov 02, 2021
Sell 11.6 K USD
STANKOVICH THOMAS
Chief Financial Officer
- 4320
2.69 USD
3 years ago
Oct 01, 2021
Sell 10.1 K USD
STANKOVICH THOMAS
Chief Financial Officer
- 3660
2.76 USD
3 years ago
Oct 01, 2021
Sell 34.8 K USD
Bandy Barton P.
President and CEO
- 12565
2.77 USD
3 years ago
Sep 10, 2021
Sell 851 K USD
Bandy Barton P.
President and CEO
- 294494
2.89 USD
3 years ago
Sep 10, 2021
Sell 140 K USD
STANKOVICH THOMAS
Chief Financial Officer
- 48366
2.89 USD
3 years ago
Sep 10, 2021
Sell 598 K USD
GLADNEY DAN W
Director
- 200000
2.99 USD
3 years ago
Aug 30, 2021
Bought 51.4 K USD
STANKOVICH THOMAS
Chief Financial Officer
+ 15000
3.429 USD
3 years ago
Aug 20, 2021
Bought 48.3 K USD
STANKOVICH THOMAS
Chief Financial Officer
+ 15000
3.219 USD
3 years ago
Jun 16, 2021
Sell 2.53 M USD
ARMISTICE CAPITAL, LLC
10 percent owner
- 388045
6.52 USD
3 years ago
Jun 16, 2021
Sell 0 USD
ARMISTICE CAPITAL, LLC
10 percent owner
- 0
0 USD
3 years ago
Jun 16, 2021
Sell 583 K USD
ARMISTICE CAPITAL, LLC
10 percent owner
- 73591
7.92 USD
3 years ago
Jun 16, 2021
Sell 0 USD
ARMISTICE CAPITAL, LLC
10 percent owner
- 0
0 USD
3 years ago
Jun 16, 2021
Sell 426 K USD
ARMISTICE CAPITAL, LLC
10 percent owner
- 50040
8.52 USD
3 years ago
Jun 16, 2021
Sell 0 USD
ARMISTICE CAPITAL, LLC
10 percent owner
- 0
0 USD
3 years ago
Jun 17, 2021
Sell 6.35 M USD
ARMISTICE CAPITAL, LLC
10 percent owner
- 1024844
6.2 USD
3 years ago
Jun 17, 2021
Sell 0 USD
ARMISTICE CAPITAL, LLC
10 percent owner
- 0
0 USD
3 years ago
Jun 17, 2021
Sell 580 K USD
ARMISTICE CAPITAL, LLC
10 percent owner
- 81366
7.13 USD
3 years ago
Jun 17, 2021
Sell 0 USD
ARMISTICE CAPITAL, LLC
10 percent owner
- 0
0 USD
3 years ago
Jun 18, 2021
Sell 3.76 M USD
ARMISTICE CAPITAL, LLC
10 percent owner
- 685583
5.48 USD
3 years ago
Jun 18, 2021
Sell 0 USD
ARMISTICE CAPITAL, LLC
10 percent owner
- 0
0 USD
4 years ago
Sep 16, 2020
Bought 1.59 K USD
STANKOVICH THOMAS
Chief Financial Officer
+ 530
3 USD
4 years ago
Aug 19, 2020
Bought 12.3 K USD
STANKOVICH THOMAS
Chief Financial Officer
+ 4105
3 USD
5 years ago
Nov 12, 2019
Bought 108 K USD
Plovanic William J.
President & CEO
+ 65000
1.6588 USD
5 years ago
Aug 06, 2019
Bought 50 K USD
Kamdar Kim P.
Director
+ 12500
4 USD
5 years ago
Aug 06, 2019
Bought 41.2 K USD
Kamdar Kim P.
Director
+ 9375
4.4 USD
5 years ago
Aug 06, 2019
Bought 1 M USD
DOMAIN PARTERS VII L P
10 percent owner
+ 250000
4 USD
5 years ago
Aug 06, 2019
Bought 825 K USD
DOMAIN PARTERS VII L P
10 percent owner
+ 187500
4.4 USD
5 years ago
Aug 06, 2019
Bought 20 K USD
Brister Mark
Chief Technology Officer
+ 5000
4 USD
5 years ago
Aug 06, 2019
Bought 16.5 K USD
Brister Mark
Chief Technology Officer
+ 3750
4.4 USD
5 years ago
Aug 06, 2019
Bought 20 K USD
MacDonald Robert J
Chief Retail Officer
+ 5000
4 USD
5 years ago
Aug 06, 2019
Bought 16.5 K USD
MacDonald Robert J
Chief Retail Officer
+ 3750
4.4 USD
5 years ago
Aug 06, 2019
Bought 20 K USD
Hussainy Nooshin
VP of Finance
+ 5000
4 USD
5 years ago
Aug 06, 2019
Bought 16.5 K USD
Hussainy Nooshin
VP of Finance
+ 3750
4.4 USD
5 years ago
Aug 06, 2019
Bought 50 K USD
Rasdal Andrew P
Exec Chairman of the Board
+ 12500
4 USD
5 years ago
Aug 06, 2019
Bought 41.2 K USD
Rasdal Andrew P
Exec Chairman of the Board
+ 9375
4.4 USD
5 years ago
Aug 06, 2019
Bought 10 K USD
VandenBerg Amy
Chief Clinical & Reg Officer
+ 2500
4 USD
5 years ago
Aug 06, 2019
Bought 8.25 K USD
VandenBerg Amy
Chief Clinical & Reg Officer
+ 1875
4.4 USD
5 years ago
Aug 06, 2019
Bought 25 K USD
HOWE LESLEY H
Director
+ 6250
4 USD
5 years ago
Aug 06, 2019
Bought 20.6 K USD
HOWE LESLEY H
Director
+ 4687
4.4 USD
5 years ago
Aug 06, 2019
Bought 30 K USD
Stevenson Sharon
Director
+ 7500
4 USD
5 years ago
Aug 06, 2019
Bought 24.8 K USD
Stevenson Sharon
Director
+ 5625
4.4 USD
5 years ago
Aug 06, 2019
Bought 100 K USD
INTERWEST PARTNERS X LP
10 percent owner
+ 25000
4 USD
5 years ago
Aug 06, 2019
Bought 82.5 K USD
INTERWEST PARTNERS X LP
10 percent owner
+ 18750
4.4 USD
6 years ago
Aug 23, 2018
Bought 100 K USD
Kamdar Kim P.
Director
+ 54945
1.82 USD
6 years ago
Aug 23, 2018
Bought 3 M USD
DOMAIN PARTERS VII L P
10 percent owner
+ 1648359
1.82 USD
6 years ago
Aug 23, 2018
Bought 2 M USD
INTERWEST PARTNERS X LP
10 percent owner
+ 1098901
1.82 USD
6 years ago
Mar 15, 2018
Bought 19.8 K USD
Drake Neil
VP Research and Development
+ 5000
3.9555 USD
6 years ago
Mar 14, 2018
Bought 21.4 K USD
Plovanic William J.
Chief Financial Officer
+ 5300
4.0352 USD
6 years ago
Mar 14, 2018
Bought 21.8 K USD
Plovanic William J.
Chief Financial Officer
+ 5412
4.036 USD
6 years ago
Mar 13, 2018
Bought 39.3 K USD
Plovanic William J.
Chief Financial Officer
+ 9700
4.0491 USD
6 years ago
Mar 13, 2018
Bought 38.8 K USD
Plovanic William J.
Chief Financial Officer
+ 9588
4.0493 USD
6 years ago
Dec 19, 2017
Sell 0 USD
Mashaal Michael Y
Director
- 20487
0 USD
8 years ago
Oct 12, 2016
Bought 201 K USD
Kamdar Kim P.
Director
+ 13400
15 USD
8 years ago
Oct 12, 2016
Bought 15 K USD
Norwood Matthew
VP of Sales
+ 1000
15 USD
7. News
ReShape Lifesciences Inc. (RSLS) Q3 2024 Earnings Call Transcript ReShape Lifesciences Inc. (NASDAQ:RSLS ) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Michael Miller - Rx Communications Paul Hickey - President and CEO Thomas Stankovich - CFO Krishna Gupta - Director, Vyome Therapeutics Conference Call Participants Jason McCarthy - Maxim Group Operator Good afternoon, and thank you for joining the ReShape Lifesciences Third Quarter 2024 Conference Call. I would like to turn the call over to Michael Miller from Rx Communications. seekingalpha.com - 2 days ago
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update Conference Call to be Held at 4:30 pm ET on Thursday, November 14, 2024 Conference Call to be Held at 4:30 pm ET on Thursday, November 14, 2024 globenewswire.com - 4 days ago
ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Health Canada has updated the Medical Device License granting approval for the company's next generation, enhanced Lap-Band® 2.0 FLEX and Tubing Kit. globenewswire.com - 4 days ago
ReShape Lifesciences® Receives NIH Supplementary Grant with the University of Southern California's Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape's Proprietary Diabetes Bloc-Stim Neuromodulation™ Technology Approximately $241,000 Grant Will Be Utilized to Conduct Minimally Invasive Laparoscopic Surgical Electrode Implantation Techniques and Long Duration Safety and Blood Glucose Modulation Experiments for the CARSS Project Approximately $241,000 Grant Will Be Utilized to Conduct Minimally Invasive Laparoscopic Surgical Electrode Implantation Techniques and Long Duration Safety and Blood Glucose Modulation Experiments for the CARSS Project globenewswire.com - 5 days ago
ReShape Lifesciences Announces 1-for-58 Reverse Stock Split IRVINE, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Board of Directors has declared a 1-for-58 reverse stock split of the company's common stock, which will be effective for trading purposes upon the commencement of trading on September 23, 2024. globenewswire.com - 1 month ago
ReShape Lifesciences Inc. (RSLS) Q2 2024 Earnings Call Transcript ReShape Lifesciences Inc. (NASDAQ:RSLS ) Q2 2024 Earnings Conference Call August 15, 2024 4:30 PM ET Company Participants Michael Miller - IR Paul Hickey - President and CEO Thomas Stankovich - CFO Krishna Gupta - Director, Vyome Therapeutics Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the ReShape Lifesciences Second Quarter 2024 Earnings Call. seekingalpha.com - 3 months ago
ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update Conference Call to be Held at 4:30 pm ET on Thursday, August 15, 2024 Conference Call to be Held at 4:30 pm ET on Thursday, August 15, 2024 globenewswire.com - 3 months ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHUY, RSLS on Behalf of Shareholders NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: globenewswire.com - 3 months ago
RESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ReShape Lifesciences Inc. - RSLS NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of ReShape Lifesciences Inc. (the “Company”) (NasdaqCM: RSLS) and Vyome Therapeutics, Inc. Under the terms of the Proposed Transaction, ReShape shareholders will own approximately 11.1% of the combined company immediately following the closing of the merger, subject to adjustment based on ReShape's actual net c. businesswire.com - 4 months ago
RSLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of ReShape Lifesciences Inc. Is Fair to Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of ReShape Lifesciences Inc. (NASDAQ: RSLS) and Vyome Therapeutics, Inc. is fair to ReShape shareholders. Under the terms of the Proposed Transaction, ReShape shareholders will own approximately 11.1% of the combined company immediately following the closing of the merger, subject to adjustment based on ReShape's actual net cash at closing compared to a target net cash amount of $5 mill. businesswire.com - 4 months ago
Vyome to go public and trade on the Nasdaq Capital Market under the ticker symbol “HIND” CAMBRIDGE, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Vyome Therapeutics, a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, announced today that it has signed a merger agreement with ReShape Lifesciences (Nasdaq: RSLS). globenewswire.com - 4 months ago
ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys ReShape and Vyome, a Clinical Stage Specialty Pharmaceutical Company Working To Treat Immuno-Inflammatory Diseases of Unmet Need, to Combine in All-Stock Merger globenewswire.com - 4 months ago
8. Profile Summary

ReShape Lifesciences Inc. RSLS

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 2.65 M
Dividend Yield 0.00%
Description ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.
Contact 1001 Calle Amanecer, San Clemente, CA, 92673 https://www.reshapelifesciences.com
IPO Date Oct. 6, 2016
Employees 29
Officers Mr. Naqeeb A. Ansari Senior Vice President of Global Commercial Operations Jody B. Dahlman Director of Communications Mr. Al Diaz Vice President of Operations and R&D Mr. Paul F. Hickey Chief Executive Officer, President & Director Mr. Thomas Stankovich Senior Vice President & Chief Financial Officer Dr. Katherine S. Tweden Ph.D. Co-Founder Dr. Dov Gal D.V.M., M.B.A. Vice President of Regulatory Clinical Quality & Compliance Officer Dr. Mark B. Knudson Ph.D. Co-Founder and Special Advisor to the Chief Executive Officer Mr. Dan W. Gladney Executive Chair